(Q42171251)

17 October 2017

title

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals (English)

1 reference

17 October 2017

1 reference

Carol H Wysham

1

1 reference

17 October 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

17 October 2017

published in

Postgraduate Medicine

1 reference

17 October 2017

volume

122

1 reference

17 October 2017

issue

3

1 reference

17 October 2017

page(s)

52-60

1 reference

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Glycemic control in type 2 diabetes: time for an evidence-based about-face?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Relationship of metabolic risk factors and development of cardiovascular disease and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Type II diabetic subjects lose less weight than their overweight nondiabetic spouses

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Weight loss in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

National trends in treatment of type 2 diabetes mellitus, 1994-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Medication taking and diabetes: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Processes of care desired by elderly patients with multimorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Clinical outcomes and adherence to medications measured by claims data in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Factors associated with first-fill adherence rates for diabetic medications: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Impact of fixed-dose combination drugs on adherence to prescription medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Impact of dosage frequency on patient compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

Beyond "compliance" is "adherence". Improving the prospect of diabetes care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2142

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2142

1 reference

17 October 2017

1 reference